Učitavanje...
Brief Report: A Phase II “Window-of-Opportunity” Frontline Study of the mTOR Inhibitor, Temsirolimus Given as a Single Agent in Patients with Advanced NSCLC, an NCCTG Study
BACKGROUND: In an effort to evaluate the single agent activity of temsirolimus in previously untreated non–small-cell lung cancer, the North Central Cancer Treatment Group undertook a frontline “window-of-opportunity” study. METHODS: Patients received 25 mg of temsirolimus administered intravenously...
Spremljeno u:
| Izdano u: | J Thorac Oncol |
|---|---|
| Glavni autori: | , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5740874/ https://ncbi.nlm.nih.gov/pubmed/22722792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31824de0d6 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|